These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 30218587

  • 21. The use of PTH in the treatment of osteoporosis.
    Borba VZ, Mañas NC.
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
    [Abstract] [Full Text] [Related]

  • 22. New Frontiers in Osteoporosis Therapy.
    Cheng C, Wentworth K, Shoback DM.
    Annu Rev Med; 2020 Jan 27; 71():277-288. PubMed ID: 31509477
    [Abstract] [Full Text] [Related]

  • 23. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK, Clarke BL.
    Maturitas; 2017 Mar 27; 97():53-60. PubMed ID: 28159062
    [Abstract] [Full Text] [Related]

  • 24. [Osteoanabolics and the forthcoming drugs for the treatment of osteoporosis].
    Grazio S.
    Reumatizam; 2014 Mar 27; 61(2):95-9. PubMed ID: 25427402
    [Abstract] [Full Text] [Related]

  • 25. Current Status of Bone-Forming Therapies for the Management of Osteoporosis.
    Sølling ASK, Harsløf T, Langdahl B.
    Drugs Aging; 2019 Jul 27; 36(7):625-638. PubMed ID: 31066015
    [Abstract] [Full Text] [Related]

  • 26. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 27; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 27. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V, Clarke BL.
    Maturitas; 2012 Nov 27; 73(3):269-72. PubMed ID: 22925430
    [Abstract] [Full Text] [Related]

  • 28. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT, Christensen PM, Ejersted C, Langdahl BL.
    Basic Clin Pharmacol Toxicol; 2004 Jun 27; 94(6):260-70. PubMed ID: 15228497
    [Abstract] [Full Text] [Related]

  • 29. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D, Beckett T, Kourtjian E, Messingschlager C, Sipahi R, Padley M, Stubbart J.
    Osteoporos Int; 2018 Jun 27; 29(6):1351-1357. PubMed ID: 29541794
    [Abstract] [Full Text] [Related]

  • 30. Abaloparatide (Tymlos) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Jun 19; 59(1523):97-98. PubMed ID: 28609423
    [No Abstract] [Full Text] [Related]

  • 31. A practical approach for anabolic treatment of bone fragility with romosozumab.
    Cianferotti L, Cipriani C, Palermo A, Viapiana O, Zavatta G, Mazziotti G.
    J Endocrinol Invest; 2024 Nov 19; 47(11):2649-2662. PubMed ID: 38789679
    [Abstract] [Full Text] [Related]

  • 32. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
    O'Hanlon CE, Parthan A, Kruse M, Cartier S, Stollenwerk B, Jiang Y, Caloyeras JP, Crittenden DB, Barron R.
    Clin Ther; 2017 Jul 19; 39(7):1276-1290. PubMed ID: 28629610
    [Abstract] [Full Text] [Related]

  • 33. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
    Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D.
    Osteoporos Int; 2018 Feb 19; 29(2):323-328. PubMed ID: 29167971
    [Abstract] [Full Text] [Related]

  • 34. The role of osteoanabolic agents in the management of patients with osteoporosis.
    McClung MR, Rothman MS, Lewiecki EM, Hanley DA, Harris ST, Miller PD, Kendler DL.
    Postgrad Med; 2022 Aug 19; 134(6):541-551. PubMed ID: 35635798
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.